Beigene Stock

Beigene ROA

Delisted·Jun 18, 2026

The Return on Assets (ROA) of Beigene (6160.HK) as of Aug 24, 2026 is 3.59 %. In the previous year, Return on Assets (ROA) was -10.89 % — a change of -132.92% (higher).

ROA

3.59 %

YoY

-132.92%

Last updated:

In 2026, Beigene's return on assets (ROA) was 3.59 %, a -132.92% increase from the -10.89 % ROA in the previous year.

The Beigene ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-29.95 USD
Jan 1, 2019
-58.84 USD
Jan 1, 2020
-29.01 USD
Jan 1, 2021
-16.86 USD
Jan 1, 2022
-31.41 USD
Jan 1, 2023
-15.19 USD
Jan 1, 2024
-10.89 USD
Jan 1, 2025
3.59 USD
The Beigene ROA history
YEARROAYoY
3.59 %-132.92%
-10.89 %-28.30%
-15.19 %-51.65%
-31.41 %+86.29%
-16.86 %-41.88%
-29.01 %-50.69%
-58.84 %+96.46%
-29.95 %+236.63%
-8.90 %-69.71%
-29.38 %-39.93%
-48.90 %+43.47%
-34.09 %
Access this data via the Eulerpool API

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

ROA Details

Understanding Beigene's Return on Assets (ROA)

Beigene's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Beigene's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Beigene's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Beigene’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Beigene stock

Return on Assets (ROA) of Beigene is 3.59 % in 2026.

Return on Assets (ROA) of Beigene changed from -10.89 % to 3.59 %, representing a -132.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Beigene since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Beigene with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Beigene

All Key Metrics — Beigene